Voleon Capital Management LP Acquires 82,857 Shares of 10x Genomics $TXG

Key Points

• Voleon Capital Management LP significantly increased its stake in 10x Genomics by 579.7%, acquiring a total of 97,151 shares worth approximately $848,000.
• Several institutional investors have also boosted their positions in 10x Genomics, with notable increases from firms like Signaturefd LLC and PNC Financial Services Group Inc..
• 10x Genomics reported better-than-expected earnings of $0.28 per share and a revenue of $172.91 million for the last quarter, surpassing analysts' estimates.

Voleon Capital Management LP boosted its position in 10x Genomics (NASDAQ:TXG - Free Report) by 579.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 97,151 shares of the company's stock after acquiring an additional 82,857 shares during the period. Voleon Capital Management LP owned about 0.08% of 10x Genomics worth $848,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after acquiring an additional 1,614 shares during the period. Xponance Inc. grew its stake in shares of 10x Genomics by 17.4% during the 1st quarter. Xponance Inc. now owns 12,010 shares of the company's stock valued at $105,000 after buying an additional 1,778 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of 10x Genomics during the 4th quarter valued at $32,000. AlphaQuest LLC grew its stake in shares of 10x Genomics by 8.3% during the 1st quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock valued at $257,000 after buying an additional 2,258 shares during the period. Finally, Signaturefd LLC grew its stake in shares of 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after buying an additional 2,409 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,486 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Taich sold 22,315 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer owned 309,273 shares of the company's stock, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is owned by corporate insiders.

10x Genomics Price Performance

Shares of 10x Genomics stock traded up $0.26 on Monday, hitting $12.90. The company had a trading volume of 575,507 shares, compared to its average volume of 3,310,390. The business has a 50-day simple moving average of $13.21 and a 200-day simple moving average of $10.81. The company has a market cap of $1.61 billion, a PE ratio of -18.40 and a beta of 2.00. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, August 30th. Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a research note on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. UBS Group upped their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Piper Sandler began coverage on shares of 10x Genomics in a research report on Thursday. They set a "neutral" rating and a $15.00 price target for the company. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and an average target price of $13.65.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.